Satovsky Asset Management LLC Buys New Shares in Establishment Labs Holdings Inc. $ESTA

Satovsky Asset Management LLC purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 2nd quarter, Holdings Channel reports. The firm purchased 7,075 shares of the company’s stock, valued at approximately $607,000. Establishment Labs accounts for about 0.1% of Satovsky Asset Management LLC’s investment portfolio, making the stock its 26th biggest holding.

Other large investors also recently bought and sold shares of the company. KBC Group NV purchased a new position in Establishment Labs during the first quarter worth approximately $28,000. Quarry LP purchased a new stake in shares of Establishment Labs during the 3rd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Establishment Labs during the 2nd quarter valued at $43,000. Kestra Advisory Services LLC acquired a new stake in shares of Establishment Labs during the 4th quarter worth $47,000. Finally, Osaic Holdings Inc. increased its holdings in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Price Performance

Establishment Labs stock opened at $72.67 on Monday. Establishment Labs Holdings Inc. has a 52-week low of $36.53 and a 52-week high of $97.59. The firm has a fifty day moving average of $86.19 and a 200-day moving average of $74.86. The firm has a market capitalization of $2.17 billion, a P/E ratio of -55.47 and a beta of 1.07. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The business had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The business’s revenue was up 31.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.57) EPS. As a group, analysts predict that Establishment Labs Holdings Inc. will post -1.15 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ESTA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. JPMorgan Chase & Co. boosted their price target on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Thursday, August 13th. Needham & Company LLC raised their price objective on Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Mizuho lifted their price objective on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $100.25.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.